BioCentury
ARTICLE | Clinical News

ATS907: Phase IIa started

February 13, 2012 8:00 AM UTC

Altheos began a 2-stage, single-blind, dose-ranging, U.S. Phase IIa trial of once- or twice-daily ATS907 eye drops for up to 28 days in about 210 patients with primary open-angle glaucoma and/or ocula...